The Atrophic Vaginitis market is expected to grow owing to the aging population and increase in disease awareness.
DelveInsight’s Atrophic Vaginitis Market Insights report proffers a detailed comprehension of Atrophic Vaginitis market size by treatment, epidemiology, emerging therapies, Atrophic Vaginitis market share of the individual therapies, current and forecasted Atrophic Vaginitis market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Atrophic Vaginitis: Overview
Atrophic Vaginitis, also called Vaginal Atrophy, is a condition where the lining of the vagina gets drier and thinner. This results in itching, burning, and pain during sex, among other Atrophic Vaginitis symptoms. The condition also includes urinary tract problems such as Urinary Tract Infections (UTIs) and frequent urination.
For further information on Market Impact by Therapies, Download the Atrophic Vaginitis Market sample @ Atrophic Vaginitis Market Scenario
Atrophic Vaginitis Epidemiology Segmentation
The Atrophic Vaginitis Market Report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Total Prevalent cases of Atrophic Vaginitis
- Total Diagnosed Cases of Atrophic Vaginitis
- Total Atrophic Vaginitis cases by severity
- Total Patients taking Prescription treatment
Know-how Atrophic Vaginitis Epidemiological Trends are going to look like in 2032 for the 7MM by downloading @ Atrophic Vaginitis Epidemiological Insights
Some of the essential features from the Atrophic Vaginitis Market Report:
- As per the DelveInsight estimates, in the year 2021, the total prevalent cases of Atrophic Vaginitis were 95.94 million cases in the 7MM, which are expected to grow during the study period.
- The Atrophic Vaginitis current treatment includes estrogen therapy: Imvexxy, hormone replacement therapy, Systemic selective estrogen receptor modulator: Osphena and DHEA: Intrarosa
- The total Atrophic Vaginitis market size in the United States accounted for USD 2700 million in 2021 which is expected to rise during the study period.
- Key Atrophic Vcaginitis companies suchas Shionogi, Hormos Medical, QuatRx Pharmaceuticals, Pantarhei Bioscience, Mithra Pharmaceuticals, Endoceutics, AMAG Pharmaceuticals, Bayer HealthCare Pharmaceuticals Inc., Theramex, and others are currently actively working in the Atrophic Vaginitis market.
- Key Atrophic Vaginitis therapies in the pipeline include Estetrol, DHEA: Intrarosa, and others.
- In January 2019, Duchesnay announced the FDA approval of the supplemental New Drug Application (sNDA) for Osphena (ospemifene) to expand its use to include treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause.
Atrophic Vaginitis Market Outlook
Atrophic Vaginitis treatment begins with the use of over-the-counter measures such as lubricants and moisturizers, in the second line of treatment, patients use intravaginal estrogen. Intravaginal estrogen products, conjugated estrogen cream, estradiol cream, estradiol tablet, estradiol vaginal ring, and estradiol transdermal patch show equivocal relief of Atrophic Vaginitis symptoms and improvement in acidification of vaginal tissues.
Atrophic Vaginitis market dynamics are anticipated to change in the coming years owing to increase in the women in menopausal phase and increasing awareness among females for the disease. The acceptance of the disease as a health problem will be crucial for the growth of the Atrophic Vaginitis market.
Discover more about therapy set to grab substantial Atrophic Vaginitis market share @ Atrophic Vaginitis Market Landscape
Atrophic Vaginitis Pipeline Therapies and Key Companies
- Estetrol: Pantarhei Bioscience
- Prasterone Vaginal: Bayer/Endoceutics
Atrophic Vaginitis Market: Drivers and Barriers
In the past decade, research and development of diagnostic testing have allowed a modern treatment approach, giving rise to increasing awareness about Atrophic Vaginitis. In addition to that, the increasing prevalence of Atrophic Vaginitis cases, as well as the rise in the aging population, serve as certain factors for the Atrophic Vaginitis market surge in the coming years. On top of that, there’s a very less competitive scenario in the Atrophic Vaginitis market, leading to the growth of existential companies as well as the entrance of new companies will also have sufficient scope in the Atrophic Vaginitis market
On the contrary, several complications associated with the current Atrophic Vaginitis treatment options available are a factor anticipated as an obstruction in the growth of the Atrophic Vaginitis market. In addition to that, the Atrophic Vaginitis market players facing competition from generic drug manufacturers also serve as a potential drawback for the Atrophic Vaginitis market.
Know which Atrophic Vaginitis therapy is expected to score the touchdown first @ Atrophic Vaginitis Market Landscape and Forecast
Scope of the Atrophic Vaginitis Market Report
- Study Period: 2019-32
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Atrophic Vaginitis Companies: Shionogi (OTCMKTS: SGIOY), Hormos Medical, QuatRx Pharmaceuticals, Pantarhei Bioscience, Mithra Pharmaceuticals (EBR: MITRA), Endoceutics, AMAG Pharmaceuticals, Bayer HealthCare Pharmaceuticals Inc. (OTCMKTS: BAYRY), Theramex
- Key Atrophic Vaginitis Marketed Therapies: Estetrol, DHEA: Intrarosa
- Therapeutic Assessment: Atrophic Vaginitis current marketed and emerging therapies
- Market Dynamics: Atrophic Vaginitis market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs
- KOL’s views
- Analyst’s views
- Market Access and Reimbursement
Discover more about the future market share of Atrophic Vaginitis treatment therapies @ Atrophic Vaginitis Market Forecast
Table of Contents
| 1 | Key Insights |
| 2 | Report Introduction of Atrophic Vaginitis |
| 3 | Atrophic Vaginitis: Market overview at a glance |
| 4 | Executive Summary of Atrophic Vaginitis |
| 5 | Organizations contributing towards Atrophic Vaginitis |
| 6 | Disease Background and Overview of Atrophic Vaginitis |
| 7 | Management and Treatment of Atrophic Vaginitis |
| 8 | Atrophic Vaginitis Epidemiology and Patient Population |
| 9 | Atrophic Vaginitis Patient Journey |
| 10 | Atrophic Vaginitis Case Reports |
| 11 | Atrophic Vaginitis Marketed Therapies |
| 12 | Atrophic Vaginitis Emerging Therapies |
| 13 | Atrophic Vaginitis: 7 Major Market Analysis |
| 14 | Atrophic Vaginitis Market Outlook |
| 15 | Unmet Needs in Atrophic Vaginitis |
| 16 | KOL Views |
| 17 | Atrophic Vaginitis Market Drivers |
| 19 | Atrophic Vaginitis Market Barriers |
| 19 | Atrophic Vaginitis SWOT Analysis |
| 20 | Appendix |
| 21 | DelveInsight Capabilities |
| 22 | Disclaimer |
| 23 | About DelveInsight |
Get in touch with our Business executive @ Atrophic Vaginitis Market Landscape Analysis
Related Reports
DelveInsight’s, “Bacterial Vaginosis Pipeline Insight, 2022,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Bacterial Vaginosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products and key Bacterial Vaginosis companies such as Osel Inc, Evofem Biosciences, LUCA Biologics, Melinta Therapeutics, TenNor Therapeutics, Mayfield Pharmaceuticals, Toltec Pharmaceuticals, and many others.
Vaginal Rejuvenation Systems Market
Global Vaginal Rejuvenation Systems market was valued at USD 5.49 billion in 2020, growing at a CAGR of 10.14% during the forecast period from 2021 to 2026 to reach USD 9.75 billion by 2026. The report covers market trends, market drivers and barriers and key companies involved such as INTERmedic Arfran, Lumenis Be Ltd, VYDENCE® Medical, Candela Medical, Quanta System, MedArt ApS, Sincoheren Ltd, and others.
Bacterial Vaginosis Epidemiology
DelveInsight’s “Bacterial Vaginosis Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Bacterial Vaginosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Vaginal Specula/Vaginal Speculum Market
DelveInsight’s ‘Vaginal Specula/Vaginal Speculum Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Vaginal Specula/Vaginal Speculum and the historical and forecasted Vaginal Specula/Vaginal Speculum market trends, and key Vaginal Specula/Vaginal Speculum companies involved such as Welch Allyn®, BD, Aesculap AG (B. Braun Melsungen AG), Sklar Surgical Instruments, Medicon, Robinson Healthcare, Pelican Feminine Healthcare, and many others.
DelveInsight’s ‘Vaginal Pessary Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Vaginal Pessary and the historical and forecasted Vaginal Pessary market trends, and key Vaginal Pessary companies involved such as Smiths Medical, Integra LifeSciences, Thomas Medical, Personal Medical Corp, MEDGYN PRODUCTS, INC, and others.
Female Trichomoniasis Vaginalis Epidemiology
DelveInsight’s “Female Trichomoniasis Vaginalis Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Female Trichomoniasis Vaginalis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Browse Through Our Blog Post
- Preventing Cervical Cancer Through Screening And HPV Vaccines
- Widespread Usage of HPV Vaccine Reduces Cervical Cancers and Precancers
- Vulvovaginal Candidiasis
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Shruti Thakur
+1(919)321-6197